Passage BIO, Inc. is a genetic medicines company focused on developing transformative therapies for rare, monogenic CNS disorders with limited or no approved treatment options. Its vision is to become the premier genetic medicines company by developing and ultimately commercializing therapies that dramatically and positively transform the lives of patients suffering from these life-threatening disorders. To achieve its vision, it has assembled a world-class team whose members have decades of collective experience in genetic medicines and rare disease drug development and commercialization. The field of genetic medicine is rapidly expanding and it believe it has a differentiated approach to developing treatments for rare, monogenic CNS disorders that enables it to select and advance product candidates with a higher probability of technical and regulatory success. It has entered into a strategic research collaboration with Penn\u0027s GTP, headed by Dr. James Wilson, a leader in the genetic medicines field. Through this collaboration it has assembled a deep portfolio of genetic medicine product candidates, including its three lead product candidates: PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease.